{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Compound hydrolyzed protein beverage by Nanjing Zhongtiandeheng Applied Stemmedical Co., Ltd
(2024)
Source URL:
First approved in 2024
Source:
Compound hydrolyzed protein beverage by Nanjing Zhongtiandeheng Applied Stemmedical Co., Ltd
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M012
(2024)
Source URL:
First approved in 2024
Source:
M012
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2023
Source:
ANDA075357
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
PROTECT CARDIO AF by GIL Pharmaceutical Corp.
(2022)
Source URL:
First approved in 2022
Source:
PROTECT CARDIO AF by GIL Pharmaceutical Corp.
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
24hr Health Glow by USA Health
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2019)
Source URL:
First approved in 2019
Source:
21 CFR 348
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M016
(2013)
Source URL:
First approved in 2013
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT01339299: Phase 4 Interventional Completed Controlled Ovarian Stimulation
(2009)
Source URL:
First approved in 1975
Source:
BLA021663
Source URL:
Class:
PROTEIN
